Welcome to 2022! 2021 has been a year of burn outs, huge volatility and filled with epic events. I sincerely hope that everyone is well and charged up for a fresh start! In any case, this article is a simple reporting for my SRS updates.
Disclaimers: This is not and should not be taken as a buy/sell recommendation.
If you are new to SRS, I would encourage you to start from my most read SRS article, 5 Things You Need To Know About SRS to begin.
My Thoughts And Consideration
SGX:HST (Lion-OCBC Sec HSTECH S$)
The performance is not pretty. The elephant in the room continues to be my exposure into Chinese Technology Stocks (SGX:HST). You can read why I like SGX:HST in March2021 review. It continues to drag the portfolio down despite good fundamentals.
I continue to be positive in this exposure as this ETF is invested into quality Chinese companies that can deliver sustainable growth in the next 3 to 5 years. The undervalued sector has attracted Charlie Munger who has double down in to Alibaba. I have no doubt that the companies in this sector will do well and eventually the share price will follow.
SGX: BTOU (Manulife US REIT)
I first bought into SGX: BTOU as a recovery value play in the portfolio in March2021. However, things changed for BTOU as they pivoted from investing only in Class-A and Trophy assets in the traditional gateway city offices to Sun Belt states and emerging markets.
If I can create a Singapore reference, this REIT invest only into MBFC or One Raffles Place previously and are now investing into “emerging” locations like International Business Park at Jurong East or Woods Square at Woodlands. This is not a perfect reference and I hope you get the idea.
Generally, I like it when companies use data to look at emerging trends and are flexible to adapt to their new strategy. ProButtery wrote a very comprehensive article on BTOU and I very much agree with his thesis. You can find his thoughts here.
I look forward their future business performance.
Lastly, I added new capital into my SRS account for tax purposes. .
Disclaimer: this is not and should not be taken as a buy/sell recommendation. Like what Charlie Munger famously said: the big money is not in the buying or selling.. but in the waiting.
Chengkok is a licensed Financial Services Consultant since 2012. He is an Investment and Critical Illness Specialist. Wealthdojo was created in 2019 to educate and debunk “free financial advice” that was given without context.
Feel Free To Reach Out To Share Your Thoughts.
The views and opinions expressed in this publication are those of the author and do not reflect the official policy or position of any other agency, organisation, employer or company. Assumptions made in the analysis are not reflective of the position of any entity other than the author.